New Orleans – 5pm on Sunday at the annual meeting of the American Society of Hematology (ASH) saw the start of the oral sessions, where the latest research and clinical trial data is presented.

I attended the novel agents in lymphoma session, and this post offers some top-line “notes from the road” on the following presentations:

Abstract 85: Idelalisib Ph2 data in patients with double (Rituximab and Alkylating Agent) refractory indolent Non-Hodgkin Lymphoma (iNHL).

Abstract 86: SAR245409 Monotherapy in relapsed/refractory Follicular Lymphoma from phase 2 ARD12130 study.

Abstract 87: Phase 2 study of BAY 80-6946 (copanlisib) in relapsed/refactory, indolent or aggressive lymphomas.

Subscribers to premium content can read more below:

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. Please READ our TERMS OF USE before purchasing: You are NOT PERMITTED to share access or copies of posts. If you work for a CONSULTING FIRM, AGENCY, or are in PR or COMMUNICATIONS you must a purchase a CORPORATE license & cannot purchase an INDIVIDUAL license. Please CONTACT US for a quote. Rates may change without notice and are non-refundable.